Edition:
India

Ono Pharmaceutical Co Ltd (4528.T)

4528.T on Tokyo Stock Exchange

2,734JPY
18 May 2018
Change (% chg)

¥22 (+0.83%)
Prev Close
¥2,712
Open
¥2,710
Day's High
¥2,740
Day's Low
¥2,684
Volume
1,576,100
Avg. Vol
2,681,291
52-wk High
¥3,389
52-wk Low
¥2,185

Latest Key Developments (Source: Significant Developments)

Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it entered into license agreement with Bristol-Myers Squibb Company (BMS)for Prostaglandin E2 receptor antagonists relating to Immuno-Oncology programs .Under the terms of this agreement, BMS is granted the rights to develop and commercialize ONO-4578 and other compounds from PGE2 receptor antagonist programs worldwide, except Japan, South Korea, Taiwan, China and Association of South-East Asian Nations (ASEAN)countries.In accordance with this agreement, ONO receives an upfront payment of $40 million from BMS.ONO will also receive subsequent clinical, regulatory and sales-based milestone payments, as well as royalties based on sales of the products in the countries where ONO granted BMS the rights for development and commercialization.  Full Article

Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment
Thursday, 14 Dec 2017 

Dec 13 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB WILL MAKE AN UPFRONT PAYMENT OF $40 MILLION TO ONO.BRISTOL-MYERS SQUIBB-WILL BE SOLELY RESPONSIBLE FOR DEVELOPMENT, MANUFACTURING,COMMERCIALIZATION OF ONO-4578,OTHER PGE(2) RECEPTOR ANTAGONIST PRODUCTS.  Full Article

Ono Pharmaceutical completes retirement of treasury shares
Tuesday, 31 Oct 2017 

Oct 31(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it completed retirement of 45.9 million shares (7.8 percent of outstanding) on Oct. 31.Says the total shares outstanding 543.3 million shares after the retirement.  Full Article

National Investments Fund - Celyad enters into license agreement with ono pharmaceutical co., ltd. to develop allogeneic nkr-2 t-cell immunotherapy<1227.HK><4528.T>
Wednesday, 13 Jul 2016 

National Investments Fund Ltd <1227.HK>: Celyad enters into license agreement with Ono Pharmaceutical Co., Ltd. to develop allogeneic nkr-2 t-cell immunotherapy . Celyad would receive upfront payment of $12.5 million and is eligible of up to $299 million in development and commercial milestones . Celyad would also receive double digit royalties based on net sales of the licensed product in ono's territories . Under the agreement, Celyad would continue developing its allogeneic nkr-2 t-cell immunotherapy in EU and US territories . Says company is aware that Celyad s.a had published a press release on 11 July 2016 .  Full Article

Celyad says early signing agreement with ONO is because of interest of companies - conf call
Monday, 11 Jul 2016 

Celyad SA : Reason for early signing agreement with ONO Pharmaceutical <4528.T> is because of interest of companies to do so - conf call . In order for deal in US or Europe, would have to be "extremely compelling" for us at this stage - conf call . Within next 12 months we should expect second milestone - conf call . Royalty rate is same for all 3 countries - conf call . On C-Cure: discussions with EMA in Q3 - conf call . Japanese partnership has been relatively expedited - conf call Further company coverage: [CYAD.BR] (Gdynia Newsroom) ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;)).  Full Article

Celyad enters into license agreement with ONO Pharmaceutical
Monday, 11 Jul 2016 

Celyad SA : Celyad enters into license agreement with ONO pharmaceutical Co., Ltd. <4528.T> to develop allogeneic NKR-2 T-cell immunotherapy . Celyad grants an exclusive license to ONO for development and commercialization of Celyad's allogeneic NKR-2 t-cell in Japan, Korea and Taiwan . Celyad also grants to ONO an exclusive option to license its autologous NKR-2 t cell product in above ONO territories. . Total deal value of up to JPY 31.325 bln (282 mln euros or $311.5 mln) plus double digit royalties on net sales in ono territories . Celyad will receive an upfront payment of JPY 1.25 bln (11.25 million euros or $12.5 million) . Celyad is eligible of up to JPY 30.075 bln (270.75 mln euros or $299 mln) in development and commercial milestones .Will also receive double digit royalties based on net sales of licensed product in ONO's territories.  Full Article

BRIEF-Merus Says Ono Pharma Exercised Option For New Research And License Agreement

* MERUS ANNOUNCES ONO PHARMACEUTICALS EXERCISE OF ITS OPTION FOR NEW RESEARCH AND LICENSE AGREEMENT TO GENERATE BISPECIFIC ANTIBODY TARGETING AUTOIMMUNE DISEASES